Virtual screening of Osimertinib and Dacomitinib Analogues with potential activity on EGFR (T790M and l858R Mutations) for non-small cell lung cancer treatment

Virtual screening of Osimertinib and Dacomitinib Analogues with potential activity on EGFR (T790M and l858R Mutations) for non-small cell lung cancer treatment

Introduction: Tyrosine kinase inhibitors (TKIs) drugs act on epidermal growth factor (EGFR) receptors to treat Non-small cell lung cancer (NSCLC). However, mutations on EGFR receptors T790M and L858R allow just a global response rate (GRR) of 80% with Osimertinib, while Erlotinib and Gefitinib only...

Full description

Bibliographic Details
Main Authors: Leydis Luna Torres, Neyder Contreras Puentes, Antistio Avíz Amador
Format: Article
Language:Spanish
Published: Universidad de Cartagena 2021-10-01
Series:Revista Ciencias Biomédicas
Subjects:
EGFR
Osimertinib
Dacomitinib
Docking
Tyrosine kinase
Online Access:https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/3666

Internet

https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/3666

Similar Items